Adverse Drug Events Detection, Pharmacovigilance and Surveillance
"As clinical trials are performed with limited numbers of participants and limited investigation periods, they do not always clearly identify the full range of possible adverse events. Although postmarketing surveillance, which is executed by specialized agencies in many countries, has focused on gathering information on adverse drug events (ADEs), the identification of ADEs in actual clinical settings remains insufficient due to its dependence upon voluntary reporting. The introduction of electronic medical records (EMRs) by many hospitals has allowed for the secondary use of EMR data from multiple hospitals." [Teramoto K et al. JMIR Med Inform 2021;9(11):e28763; URL: https://medinform.jmir.org/2021/11/e28763]
